Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 1/20 | 0.51 |
| ▸ | ERN1 | O75460 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | NAAA | Q02083 | 3/20 | 0.40 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10303004 | 0.91 | CYP17A1 (0.55) | CYP17A1ERN1FFAR1NAAAMGLL | |
| SCHEMBL12735652 | 0.90 | CYP17A1 (0.47) | CYP17A1ERN1FFAR1NAAAMGLL | |
| SCHEMBL10301943 | 0.88 | CYP17A1 (0.52) | CYP17A1ERN1FFAR1NAAAMGLL | |
| SCHEMBL10301951 | 0.87 | S1PR1 (0.41) | CYP17A1FFAR1NAAAPTGS2 | |
| SCHEMBL12823192 | 0.85 | CYP17A1 (0.47) | CYP17A1FFAR1NAAAPTGS2 | |
| SCHEMBL12735633 | 0.85 | CYP17A1 (0.47) | CYP17A1NAAAMGLLPTGS2 | |
| SCHEMBL10301944 | 0.85 | CYP17A1 (0.49) | CYP17A1NAAAMGLLPTGS2 | |
| SCHEMBL10302220 | 0.85 | CYP17A1 (0.49) | CYP17A1ERN1FFAR1NAAAMGLL | |
| SCHEMBL12738888 | 0.83 | CYP17A1 (0.44) | CYP17A1NAAAPDGFRBPDGFRAPTGS2 | |
| SCHEMBL10303023 | 0.83 | CYP17A1 (0.47) | CYP17A1ERN1NAAAPDGFRBPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8216489-B2 | Three-ring liquid crystal compound having lateral fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-07-10 | — | — | US | disclosed |
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2011-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110037024-A1 | THREE-RING LIQUID CRYSTAL COMPOUND HAVING LATERAL FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | LEF1, LAS1L, L3MBTL3 | CYP17A1 1641/4885ERN1 837/4885FFAR1 681/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.